Standout Papers

TVB-2640 (FASN Inhibitor) ... 2008 2026 2014 2020 841
  1. TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial (2021)
    Rohit Loomba, Rizwana Mohseni et al. Gastroenterology
  2. Small Bowel Cancer in the United States (2008)
    Karl Y. Bilimoria, David J. Bentrem et al. Annals of Surgery
  3. NCCN Task Force Report: Update on the Management of Patients with Gastrointestinal Stromal Tumors (2010)
    George D. Demetri, Margaret von Mehren et al. Journal of the National Comprehensive Cancer Network

Citation Impact

1 by Nobel laureates 4 from Science/Nature 61 standout
Sub-graph 1 of 22

Citing Papers

FASN Inhibition Decreases MHC-I Degradation and Synergizes with PD-L1 Checkpoint Blockade in Hepatocellular Carcinoma
2024 Standout
A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis
2024 Standout
1 intermediate paper

Works of Jeffrey D. Wayne being referenced

TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial
2021 Standout

Author Peers

Author Oncology Epidemiology PRM Surgery Last Decade Papers Cites
Jeffrey D. Wayne 1399 825 1553 1399 65 3.4k
Enrico Giugni 4 112 24 117 8 308
Maria J. Jezewska 24 14 3 71 1.8k
K. C. Khoo 17 557
F. O. Soechting 11 335
Е. Б. Ежлова 2 69 5 41 189

All Works

Loading papers...

Rankless by CCL
2026